Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    9
    ...
ATC Name B/G Ingredients Dosage Form Price
R03AK06 SEROFLO 250 G Salmeterol (xinafoate) - 50mcg/inhalation, Fluticasone propionate - 250mcg/inhalation Inhalation suspension 1,580,359 L.L
R07AA SURFACTANTE B RICHET G Pulmonary surfactant, bovine - 200mg/8ml 200mg/8ml Suspension 26,568,472 L.L
A02BB01 MISOFAR G Misoprostol - 25mcg 25mcg Tablet 1,855,846 L.L
A10BH02 VILDIAB G Vildagliptin - 50mg 50mg Tablet 806,306 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 148,244 L.L
C03CA01 DIURESAL G Furosemide - 40mg 40mg Tablet, scored 118,258 L.L
C10AA05 TORVALIP 20 G Atorvastatin (calcium) - 20mg 20mg Tablet, film coated 972,686 L.L
G04BE08 VIVIDA 20 G Tadalafil - 20mg 20mg Tablet, film coated 1,721,398 L.L
J01MA12 EVOXIL HELLAS G Levofloxacin - 500mg/100ml 500mg/100ml Injectable solution 959,504 L.L
L01EJ01 CELEZON G Ruxolitinib - 5mg 5mg Tablet 95,532,998 L.L
M01AE51 FLUMIX BENTA G Ibuprofen - 200mg, Guaifenesin - 200mg, Chlorpheniramine maleate - 2mg, Phenylephrine HCl - 5mg Tablet, film coated 875,417 L.L
N02BE01 DOLOPAN G Paracetamol - 500mg 500mg Tablet, film coated 317,403 L.L
N04BC05 PRAMIPEXOLE BIOGARAN G Pramipexole (dihydrochloride monohydrate) - 0.7mg 0.7mg Tablet 1,733,557 L.L
R03AK06 SEROFLO-S 250 G Salmeterol (xinafoate) - 25mcg/inhalation, Fluticasone propionate - 250mcg/inhalation Inhalation suspension 1,725,494 L.L
A02BC DANLOX QUICK G Omeprazole - 20mg, Sodium bicarbonate - 1680mg Powder 1,323,685 L.L
A10BH02 VLUDIN G Vildagliptin - 50mg 50mg Tablet 767,910 L.L
B01AF02 APIXEL G Apixaban - 2.5mg 2.5mg Tablet, film coated 1,750,579 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 159,736 L.L
C03CA01 FURESIX 40 G Furosemide - 40mg 40mg Tablet 166,381 L.L
C09CA03 ANGINET G Valsartan - 80mg 80mg Tablet, film coated 387,027 L.L
C10AA05 TOVAST G Atorvastatin (calcium) - 20mg 20mg Tablet, film coated 1,127,484 L.L
D07XC01 BETA-MICOTER G Betamethasone (dipropionate) - 0.5mg/g, Clotrimazole - 10mg/g Cream 415,951 L.L
G04BE08 VIVIDA 20 G Tadalafil - 20mg 20mg Tablet, film coated 624,567 L.L
J01MA12 LEVOFLOXACIN- HAMELN G Levofloxacin - 500mg/100ml 5mg/ml Injectable solution 1,632,769 L.L
M01AE51 FLUMIX BENTA G Ibuprofen - 200mg, Guaifenesin - 200mg, Chlorpheniramine maleate - 2mg, Phenylephrine HCl - 5mg Tablet, film coated 460,746 L.L
N02BE01 FEBRADOL G Paracetamol - 500mg 500mg Tablet 327,642 L.L
N06AX11 MIRTA TAD G Mirtazapine - 30mg 30mg Tablet, film coated 1,138,235 L.L
A02BC01 ARAPRIDE G Omeprazole - 20mg 20mg Capsule, hard, gastro-resistant 427,342 L.L
A10BH02 VLUDIN G Vildagliptin - 50mg 50mg Tablet 767,910 L.L
B01AF02 APO-APIXABAN G Apixaban - 2.5mg 2.5mg Tablet 3,084,119 L.L
    ...
    9
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025